Royal Bank of Canada reissued their outperform rating on shares of Immune Design (NASDAQ:IMDZ) in a research report sent to investors on Friday, The Fly reports. The brokerage currently has a $11.00 target price on the biotechnology company’s stock.
Several other equities analysts also recently issued reports on IMDZ. Zacks Investment Research raised Immune Design from a hold rating to a buy rating and set a $5.00 target price on the stock in a research report on Tuesday, June 19th. HC Wainwright started coverage on Immune Design in a research report on Wednesday, August 29th. They set a buy rating and a $11.00 price target on the stock. Finally, Leerink Swann downgraded Immune Design from an outperform rating to a market perform rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $8.40.
Shares of NASDAQ IMDZ traded down $0.94 during mid-day trading on Friday, hitting $1.85. The stock had a trading volume of 3,329,086 shares, compared to its average volume of 342,327. Immune Design has a twelve month low of $1.47 and a twelve month high of $11.05. The company has a market cap of $166.17 million, a price-to-earnings ratio of -1.06 and a beta of 1.77.
Institutional investors and hedge funds have recently made changes to their positions in the business. Tiverton Asset Management LLC acquired a new stake in Immune Design during the 2nd quarter worth about $176,000. Essex Investment Management Co. LLC acquired a new stake in Immune Design during the 2nd quarter worth about $192,000. Bank of America Corp DE grew its position in Immune Design by 231.9% during the 2nd quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 32,669 shares during the period. DRW Securities LLC grew its position in Immune Design by 59.2% during the 2nd quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 21,900 shares during the period. Finally, Alps Advisors Inc. acquired a new stake in Immune Design during the 2nd quarter worth about $318,000. 49.41% of the stock is currently owned by institutional investors.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Recommended Story: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.